Bispecific Monoclonal Antibodies Market Report 2025 (Global Edition)

Global Bispecific Monoclonal Antibodies Market Report 2024 Market Size Split by Type Outlook: (Fragment-Based Antibodies, IgG-Based Antibodies), by Application Outlook: (Cancer, Haemophilia, Other Non...

Bispecific Monoclonal Antibodies Market Report Description

We have various report editions of Bispecific Monoclonal Antibodies Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Bispecific Monoclonal Antibodies Market Insights Video

Competitive Landscape of the Bispecific Monoclonal Antibodies Market

In the Bispecific Monoclonal Antibodies market's competitive landscape, numerous key competitors are driving innovation and growth. Companies are using several methods, including strategic alliances, collaborations, mergers and acquisitions, regional growth, and product/service launches, to augment their market position.

In August 2023, Janssen Pharmaceutical announced the FDA's clearance of TALVEY™ (talquetamab-tgvs) for the treatment of adult patients with relapsed or refractory multiple myeloma. (Source: https://www.jnj.com/media-center/press-releases/u-s-fda-approves-talvey-talquetamab-tgvs-a-first-in-class-bispecific-therapy-for-the-treatment-of-patients-with-heavily-pretreated-multiple-myeloma) In June 2023, Gentech reported the FDA's clearance of a fixed-duration bispecific antibody for patients with relapsed/refractory diffuse large B-cell lymphoma. (Source: https://www.gene.com/media/news-features/fda-approves-genentechs-fixed-duration-bispecific-antibody-for-relapsed-refractory-diffuse-large-b-cell-lymphoma) In May 2023, AbbVie announced the FDA approval of EPKINLYTM, the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma. (Source: https://news.abbvie.com/2023-05-19-EPKINLY-TM-epcoritamab-bysp-Approved-by-U-S-FDA-as-the-First-and-Only-Bispecific-Antibody-to-Treat-Adult-Patients-with-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma-DLBCL)

Top Companies Market Share in Bispecific Monoclonal Antibodies Industry: (In no particular order of Rank)

• Adimab
• Innovent Biologics
• Inc (U.S.)
• Affimed GmbH (China)
• Amgen Inc (Germany)
• AstraZeneca (U.K.)
• Xencor (U.S.)
• Sanofi (France)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Regeneron Pharmaceuticals Inc (U.S.)
• Eli Lilly (U.S.)
• Pieris Pharmaceuticals
• Inc (U.S.)
• Mereo BioPharma Group plc (U.K)
• Sobi
• TG Therapeutics Inc (Swden)
• Merus (Netherlands)
• MacroGenics
• Inc (U.S.)
• Genmab A/S (Denmark)
• Emergent BioSolutions Inc (U.S.)
• Alteogen (South Korea)
• Astellas Pharma Inc (Japan)
• Novartis AG (Switzerland)
• CELGENE CORPORATION (U.S.)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Bispecific Monoclonal Antibodies Market

Which Region Dominates the Bispecific Monoclonal Antibodies Market in 2024?

According to Cognitive Market Research, North America currently dominates the Bispecific Monoclonal Antibodies market, and the region is expected to have significant growth during the projected period. The substantial expansion can be ascribed to the initiatives and advances of various market participants, alongside technical innovations, considerable R&D expenditures, and increasing demand for bispecific antibodies—factors that have substantially augmented North America's bispecific antibody market.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR), owing to the rising disposable income, the presence of a substantial patient population for monoclonal antibody cancer therapies, and the growing emphasis on healthcare. Countries like India and China have appealing investment potential for clinical research and are expected to enhance research and development opportunities for monoclonal antibodies (mAbs).

The current report Scope analyzes Bispecific Monoclonal Antibodies Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Bispecific Monoclonal Antibodies Market

According to Cognitive Market Research, the global Bispecific Monoclonal Antibodies market size was estimated at USD 8851.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 3540.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 43.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Bispecific Monoclonal Antibodies market with a market size of USD 2793.44 million in 2024 and is anticipated to grow at a CAGR of 43.2% during the projected period. The U.S. market's increasing incidence of chronic illnesses and progress in antibody engineering technologies.
• The Canada Bispecific Monoclonal Antibodies market had a market share of USD 424.86 million in 2024 and is anticipated to grow at a CAGR of 44.2% during the projected period. Canada’s increasing investment in biotechnology and rising demand for individualized medicine.
• The Mexico Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 43.9% during the projected period, with a market size of USD 322.18 million in 2024.

Europe Bispecific Monoclonal Antibodies Market

According to Cognitive Market Research, the global Bispecific Monoclonal Antibodies market size was estimated at USD 8851.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 2655.36 million in 2024 and will grow at a compound annual growth rate (CAGR) of 43.7% from 2024 to 2031.

• The United Kingdom Bispecific Monoclonal Antibodies market had a market share of USD 446.10 million in 2024 and is anticipated to grow at a CAGR of 44.5% during the projected period. In the UK, advantageous regulatory frameworks and a strong emphasis on precision medicine.
• The France Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 42.9% during the projected period, with a market size of USD 244.29 million in 2024.
• According to Cognitive Market Research, the German Bispecific Monoclonal Antibodies market size was valued at USD 525.76 million in 2024 and is anticipated to grow at a CAGR of 43.9% during the projected period. In Germany, substantial investment in research and development and technical innovations.
• The Italy Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 43.1% during the projected period, with a market size of USD 228.36 million in 2024.
• The Russia Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 42.7% during the projected period, with a market size of USD 411.58 million in 2024.
• The Spain Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 42.8% during the projected period with a market size of USD 217.74 million in 2024
• The Luxembourg Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 43.8% during the projected period, with a market size of USD 82.32 million in 2024.
• The Portugal Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 43.5% during the projected period, with a market size of USD 55.76 million in 2024.
• The Greece Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 44.0% during the projected period, with a market size of USD 31.86 million in 2024.
• The Rest of Europe's Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 42.4% during the projected period, with a market size of USD 411.58 million in 2024.

Asia Pacific Bispecific Monoclonal Antibodies Market

According to Cognitive Market Research, the global Bispecific Monoclonal Antibodies market size was estimated at USD 8851.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 2035.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 47.2% from 2024 to 2031.

• According to Cognitive Market Research, the China Bispecific Monoclonal Antibodies market size was valued at USD 916.10 million in 2024 and is anticipated to grow at a CAGR of 46.7% during the projected period. Bispecific Monoclonal Antibodies surged in China due to regulatory changes and rapid market growth.
• The Japan Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 45.7% during the projected period, with a market size of USD 280.94 million in 2024.
• The India Bispecific Monoclonal Antibodies market had a market share of USD 244.29 million in 2024 and is anticipated to grow at a CAGR of 49.0% during the projected period. India's rising incidence of cancer and autoimmune disorders with developments in antibody engineering technologies.
• The South Korean Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 46.3% during the projected period, with a market size of USD 203.58 million in 2024.
• The Australian Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 46.9% during the projected period, with a market size of USD 105.86 million in 2024.
• The South East Asia Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 48.2% during the projected period, with a market size of USD 140.47 million in 2024.
• The Rest of Asia Pacific Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 47.0% during the projected period, with a market size of USD 144.54 million in 2024.

South America Bispecific Monoclonal Antibodies Market

According to Cognitive Market Research, the global Bispecific Monoclonal Antibodies market size was estimated at USD 8851.2 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 442.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 44.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Bispecific Monoclonal Antibodies market size was valued at USD 189.42 million in 2024 and is anticipated to grow at a CAGR of 45.2% during the projected period. Bispecific Monoclonal Antibodies flourished in Brazil due to Increased capital investment by principal market participants and growth in consumer demand.
• Argentina's Bispecific Monoclonal Antibodies market had a market share of USD 74.35 million in 2024 and is anticipated to grow at a CAGR of 45.5% during the projected period. Argentina's increasing incidence of cancer and escalating spending in targeted therapies.
• Colombia Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 44.4% during the projected period, with a market size of USD 39.39 million in 2024.
• Peru Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 44.8% during the projected period, with a market size of USD 36.29 million in 2024.
• Chile Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 44.9% during the projected period, with a market size of USD 31.86 million in 2024.
• The Rest of Latin America's Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 43.7% during the projected period, with a market size of USD 71.25 million in 2024.

Middle East and Africa Bispecific Monoclonal Antibodies Market

According to Cognitive Market Research, the global Bispecific Monoclonal Antibodies market size was estimated at USD 8851.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 177.02 million in 2024 and will grow at a compound annual growth rate (CAGR) of 44.9% from 2024 to 2031..

• The GCC Countries Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 45.7% during the projected period, with a market size of USD 75.77 million in 2024. Bispecific Monoclonal Antibodies sales flourish due to the economic feasibility and evolving legal frameworks.
• The Egypt Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 45.2% during the projected period, with a market size of USD 18.59 million in 2024.
• The South Africa Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 45.9% during the projected period, with a market size of USD 27.97 million in 2024. Bispecific Monoclonal Antibodies sales flourished in South Africa due to escalating usage of sophisticated technology and growing spending in research and development.
• The Turkey Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 44.4% during the projected period, with a market size of USD 15.22 million in 2024.
• The Nigeria Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 44.0% during the projected period, with a market size of USD 18.59 million in 2024.
• The Rest of the MEA Bispecific Monoclonal Antibodies market is anticipated to see growth at a CAGR of 43.9% during the projected period, with a market size of USD 20.89 million in 2024.

Bispecific Monoclonal Antibodies Market Analysis

How are Segments Performing in the Global Bispecific Monoclonal Antibodies Market?

Bispecific Monoclonal Antibodies Market Type Segment Analysis

According to Cognitive Market Research, IgG-Based Antibodies Bispecific Monoclonal Antibodies are likely to dominate the Bispecific Monoclonal Antibodies Market over the forecast period. Their supremacy is ascribed to their robust effectiveness and safety profiles, together with their capacity to effectively activate the immune system. IgG-based antibodies have been thoroughly researched and are often used in several therapeutic applications, including cancer and autoimmune disorders.

The Fragment-Based Antibodies is the fastest-growing segment in the Bispecific Monoclonal Antibodies Market. This rapid expansion is propelled by their diminutive size, facilitating superior tissue infiltration and expedited elimination from the organism, rendering them exceptionally efficacious in targeting neoplasms and other pathological areas. Moreover, progress in antibody engineering technology has enabled the creation of more efficient and adaptable fragment-based antibodies, hence expediting their acceptance.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Bispecific Monoclonal Antibodies Industry. Request a Free Sample PDF!

Bispecific Monoclonal Antibodies Market Application Segment Analysis

According to Cognitive Market Research, the Cancer segment holds the largest share of the market. Bispecific antibodies are sought since cancer treatments are a worldwide health issue. These antibodies target numerous tumor-associated antigens concurrently, improving treatment efficacy. Some cancers have few therapy choices. By targeting various cancer-promoting pathways or antigens, bispecific antibodies are promising. They have less side effects and toxicity than traditional medicines because they target cancer cells or tumor-associated antigens without harming healthy cells. Bispecific antibodies may improve cancer therapy results due to this property.

In the Bispecific Monoclonal Antibodies Market, the Haemophilia has been expanding at a rapid pace. The escalating prevalence of haemophilia and the substantial progress made in bispecific antibody therapies that target this condition are the primary factors driving this rapid growth. Emicizumab, a bispecific antibody that has demonstrated exceptional efficacy in the reduction of hemorrhage episodes in haemophilia patients, is one particular example. The sector's expansion has been further invigorated by the increase in research activities and clinical trials that are dedicated to the development of innovative remedies for haemophilia.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion